XmAb 942
Alternative Names: XmAb-942Latest Information Update: 12 Aug 2026
At a glance
- Originator Xencor
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
- Phase I/II Inflammatory bowel diseases
Most Recent Events
- 04 May 2026 Adverse event, pharmacodynamics and pharmacokinetics data from a phase I trial in Ulcerative colitis released by Xencor
- 02 May 2026 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I/II trial in Inflammatory bowel disease presented at the Digestive Disease Week 2026 (DDW-2026)
- 06 Aug 2025 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in Unknown location (SC)